To identify issues in the rare disease environment so that all stakeholders can effectively address key challenges and more effectively establish the value of new and existing diagnostics and therapeutics.


Rare disease is a rapidly expanding area of research and clinical development. Advancements in genetic understanding and other scientific breakthroughs have led to improved identification of rare conditions and possible pathways for improving rare disease diagnosis and treatment, as well as stratifying relatively common diseases into many rarer ones.

As clinicians are better able to diagnose specific rare diseases, new treatments are becoming available for clinical development. However, treatments for rare diseases are typically available at much higher "per patient" cost, which (along with other factors) create challenges to payers, providers and patients.

Work Products

Manuscripts & Reports



Sheela Upadhyaya

Rare Disease & RAPID C19 Strategy Adviser, NICE
London, LON, United Kingdom


Jamie O'Hara

CEO, Health Economics
Daresbury, CHW, United Kingdom

Operation Lead

Persefoni Kritikou, MSc, PhD

RWE Manager, HCD Economics
Athens, A1, Greece

Working Groups

Member Engagement

These activities allow for a variety of members to participate and also facilitates disseminating content.


Eric Low, MSc

Independent Healthcare Consultant, Eric Low Consulting
Haddington, ELN, United Kingdom

Brian O'Mahony

CEO, Irish Haemophilia Society
Dublin, D, Ireland

Questions or ideas? Please send an email to rarediseaseSIG@ispor.org

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now